Month in Review
April was defined less by new standards of care and more by clarifying boundaries. In advanced NSCLC, SKYSCRAPER-06 adds another negative phase III signal for broad TIGIT escalation, while ADC studies continue to move the field toward biomarker-defined use rather than empiric addition to existing regimens. Radiotherapy also featured prominently, with IASLC consensus guidance and early ctDNA data reinforcing the need to better select patients for local intensification. In SCLC, both radiation dose escalation and chemotherapy sensitization produced clinically interesting signals, but remain limited by retrospective or small phase II designs. Overall, the month highlights a recurring theme: escalation is only useful when patient selection, sequencing, and toxicity are carefully controlled.
Core Studies
Immunotherapy
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous NSCLC: SKYSCRAPER-06
JAMA Oncology
Study: Phase III randomized trial comparing tiragolumab plus atezolizumab plus platinum–pemetrexed chemotherapy versus placebo plus pembrolizumab plus chemotherapy in previously untreated advanced nonsquamous NSCLC without actionable EGFR/ALK alterations.
Key data: N = 542. Median PFS 8.3 vs 9.9 months; HR 1.27. Median OS 18.9 vs 23.1 months; HR 1.33. ORR 50.2% vs 56.6%. Grade 3–4 AEs 61.4% vs 60.7%; grade 5 AEs 10.1% vs 5.9%. Trial terminated after primary endpoints were not met.
Why it matters: Further weakens broad use of TIGIT inhibition as unselected first-line escalation in metastatic NSCLC.
Clinical context & caveats: Comparator was an active standard regimen. Outcomes were numerically worse with tiragolumab/atezolizumab/chemotherapy, despite similar rates of grade 3–4 toxicity.
Targeted Therapy & ADCs
Datopotamab Deruxtecan in Advanced NSCLC: ICARUS-LUNG01
Cancer Cell
Study: Prospective multicenter phase II study evaluating datopotamab deruxtecan in 100 pretreated patients with advanced NSCLC, with integrated longitudinal biomarker analyses.
Key data: ORR 26.0%; median PFS 3.6 months; median OS 11.9 months. ORR was 30.5% in nonsquamous tumors and 5.6% in squamous tumors. Grade ≥3 TRAEs occurred in 24.0%; treatment discontinuation due to TRAEs in 18.0%; three grade 5 toxicities were reported.
Why it matters: Supports clinical activity of Dato-DXd and highlights that ADC response may depend on target localization, payload sensitivity, and immune context rather than target expression alone.
Clinical context & caveats: Single-arm phase II study. TROP2 cytoplasmic staining, DNA repair activation, and immune-related pathway changes are exploratory and need validation before clinical use.
Radiotherapy
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: IASLC Consensus Statement
Journal of Thoracic Oncology
Study: IASLC multidisciplinary consensus statement evaluating evidence for definitive-dose radiotherapy to the primary lung tumor in stage IV NSCLC, including actionable genomic alteration and non-actionable populations.
Key data: Strongest randomized evidence supports early RT in EGFR-mutant oligometastatic NSCLC. In non-AGA populations, direct randomized evidence isolating primary-tumor irradiation remains limited. Consensus emphasizes individualized dose, timing, target volumes, and toxicity monitoring.
Why it matters: Provides a practical framework for when aggressive thoracic RT may be reasonable in metastatic NSCLC.
Clinical context & caveats: Evidence is strongest in EGFR-mutant oligometastatic disease. For non-AGA NSCLC, current data remain insufficient for broad treatment recommendations.
Biomarkers & Local Therapy
Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic NSCLC Treated With Radiotherapy
Clinical Cancer Research
Study: Prospective phase II discovery cohort with external validation evaluating circulating tumor fraction estimate (ctFE), derived from a tumor-naïve commercial ctDNA assay, in locally advanced and oligometastatic NSCLC treated with radiotherapy.
Key data: Discovery cohort: N = 26 unresectable stage IIB–III NSCLC; validation cohorts: locally advanced NSCLC N = 94 and oligometastatic NSCLC N = 309. Baseline ctFE was prognostic for OS (HR 5.93) and PFS (HR 11.08). Mid-treatment ctFE remained prognostic for OS (HR 7.08) and PFS (HR 12.06). Molecular response groups separated OS: 60.8 vs 13.0 vs 2.9 months.
Why it matters: Suggests early ctDNA dynamics could help identify patients who may need treatment adaptation during radiotherapy.
Clinical context & caveats: Promising biomarker study, but not yet practice-changing. ctFE thresholds, assay dependence, and clinical actionability require prospective validation.
Other Notable Publications
ADCs / Immunotherapy
Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in First-Line Metastatic NSCLC: EVOKE-02
Clinical Cancer Research
Study: Phase II multicohort study evaluating sacituzumab govitecan plus pembrolizumab and carboplatin in previously untreated metastatic NSCLC without actionable genomic alterations.
Key data: Nonsquamous N = 54; squamous N = 41. ORR 45.1% in nonsquamous and 39.0% in squamous disease. Median PFS 8.1 and 8.3 months, respectively. ORR was 66.7% in PD-L1 TPS ≥50%. SG dose was reduced to 7.5 mg/kg because of myelosuppression. Grade ≥3 TEAEs occurred in 86.4%; discontinuation of any study drug in 18.2%.
Why it matters: Shows activity for ADC–IO–chemotherapy combinations, but toxicity and lack of clear superiority limit immediate relevance.
Clinical context & caveats: Phase II, non-comparative cohorts. The authors note efficacy was not superior to current standards, so this remains hypothesis-generating.
SCLC
High-Dose Hyperfractionated SIB Radiotherapy in Limited-Stage SCLC
Practical Radiation Oncology
Study: Retrospective real-world cohort comparing 54 Gy twice-daily high-dose hyperfractionated SIB radiotherapy with 45 Gy twice-daily and 60–70 Gy once-daily thoracic RT in limited-stage SCLC.
Key data: N = 353. Median rwPFS 29.7 months with 54 Gy vs 15.0 months with 45 Gy and 13.5 months with 60–70 Gy. Median OS 63.9 vs 42.9 vs 38.0 months. Treatment-related toxicities were similar across groups.
Why it matters: Supports moderate dose escalation within a twice-daily framework as a potentially effective approach in LS-SCLC.
Clinical context & caveats: Retrospective single-center study over a long treatment period. Residual confounding and evolving supportive care remain important limitations.
Nab-Paclitaxel Plus Simvastatin as Second-Line Treatment in SCLC
BMC Medicine
Study: Randomized phase II trial comparing nab-paclitaxel plus simvastatin versus nab-paclitaxel alone in patients with SCLC after progression on first-line chemotherapy.
Key data: N = 40 enrolled; 32 included in efficacy analysis. DCR 92.9% vs 44.4%; ORR 50.0% vs 11.1%. Median PFS 113 vs 62 days; HR 0.42. No significant OS difference; median OS 208 vs 204 days. Grade ≥3 hematologic toxicity was numerically lower with simvastatin, particularly neutropenia 7.1% vs 22.2%.
Why it matters: Suggests chemotherapy sensitization may still be relevant in relapsed SCLC, especially where newer agents are unavailable.
Clinical context & caveats: Very small open-label phase II trial with only 32 evaluable patients. PFS benefit did not translate into OS improvement.
Expert Takeaways
Broad TIGIT escalation in unselected first-line NSCLC remains unsupported after SKYSCRAPER-06.
ADC development is shifting from “add the drug” to “identify who benefits and why.”
Definitive thoracic RT in metastatic NSCLC is most defensible in selected oligometastatic or actionable-driver contexts.
ctDNA dynamics during radiotherapy may become a practical tool for risk-adapted local and systemic treatment strategies.
SCLC dose escalation and chemotherapy sensitization remain active areas, but current data require prospective confirmation.
Notes on generalizability & bias signals
SKYSCRAPER-06 used a strong active comparator, making the negative result clinically meaningful.
ICARUS-LUNG01 and EVOKE-02 are phase II studies; neither should be interpreted as practice-changing.
The ctFE study is promising but assay-dependent and not yet linked to a validated treatment-adaptation strategy.
The LS-SCLC radiotherapy study is retrospective and single-center, with treatment-era effects despite IPTW adjustment.
The nab-paclitaxel/simvastatin SCLC trial is small and open-label, with no OS improvement.
Disclaimer: Publication dates reflect journal issue month; some articles may have appeared online earlier ahead of print.
If you found this useful, subscribe to receive next month’s synthesis.
Know a colleague who would benefit? Forward this issue.
Refer a colleague